Corbus Pharma (NASDAQ: CRBP) reported Q3 EPS of ($0.26), $0.04 worse than the analyst estimate of ($0.22). Revenue for the quarter came in at $1.09 million versus the consensus estimate of $1.23 million.

“The third quarter was marked by the completion of the Jenrin transaction, which we view as a transformative development for the Company,” commented Yuval Cohen, Ph.D., Chief Executive Officer of Corbus. “Our expanded pipeline of ECS-targeting drug candidates is now diversified with lenabasum, our lead late-stage clinical asset in four rare inflammatory indications with expected clinical read-out in 2020, together with CRB-4001, which is expected to enter the clinic in 2019 as a novel candidate for nonalcoholic steatohepatitis, or NASH. We have progressed in securing a platform for potential future growth for our Company from our library of over 600 compounds targeting ECS pathways.”

For earnings history and earnings-related data on Corbus Pharma (CRBP) click here.